Zhu Junlan, Zhang Jingjie, Huang Haishan, Li Jingxia, Yu Yonghui, Jin Honglei, Li Yang, Deng Xu, Gao Jimin, Zhao Qinshi, Huang Chuanshu
Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York. Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, School of Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York.
Cancer Prev Res (Phila). 2014 Dec;7(12):1270-81. doi: 10.1158/1940-6207.CAPR-14-0233. Epub 2014 Oct 3.
Cheliensisin A (Chel A), as a novel styryl-lactone isolated from Goniothalamus cheliensis Hu, has been demonstrated to have an inhibition of EGF-induced Cl41 cell transformation via stabilizing p53 protein in a Chk1-dependent manner, suggesting its chemopreventive activity in our previous studies. However, its underlying molecular mechanisms have not been fully characterized yet. In the current study, we found that Chel A treatment could increase c-Jun protein phosphorylation and activation, whereas the inhibition of c-Jun phosphorylation, by ectopic expression of a dominant-negative mutant of c-Jun, TAM67, reversed the Chel A inhibition of EGF-induced cell transformation and impaired Chel A induction of p53 protein and apoptosis. Moreover, our results indicated that Chel A treatment led to a PHLPP downregulation by promoting PHLPP protein degradation. We also found that PHLPP could interact with and bind to c-Jun protein, whereas ectopic PHLPP expression blocked c-Jun activation, p53 protein and apoptotic induction by Chel A, and further reversed the Chel A inhibition of EGF-induced cell transformation. With the findings, we have demonstrated that Chel A treatment promotes a PHLPP protein degradation, which can bind to c-Jun and mediates c-Jun phosphorylation, and further leading to p53 protein induction, apoptotic responses, subsequently resulting in cell transformation inhibition and chemopreventive activity of Chel A.
千里光辛A(Chel A)是从海南哥纳香中分离得到的一种新型苯乙烯基内酯,在我们之前的研究中已证明它通过以Chk1依赖的方式稳定p53蛋白来抑制表皮生长因子(EGF)诱导的Cl41细胞转化,表明其具有化学预防活性。然而,其潜在的分子机制尚未完全阐明。在本研究中,我们发现Chel A处理可增加c-Jun蛋白的磷酸化和激活,而通过异位表达c-Jun的显性负性突变体TAM67抑制c-Jun磷酸化,可逆转Chel A对EGF诱导的细胞转化的抑制作用,并削弱Chel A诱导的p53蛋白表达和细胞凋亡。此外,我们的结果表明,Chel A处理通过促进PHLPP蛋白降解导致其下调。我们还发现PHLPP可与c-Jun蛋白相互作用并结合,而异位表达PHLPP可阻断Chel A诱导的c-Jun激活、p53蛋白表达和细胞凋亡,并进一步逆转Chel A对EGF诱导的细胞转化的抑制作用。基于这些发现,我们证明了Chel A处理促进了PHLPP蛋白降解,PHLPP可与c-Jun结合并介导c-Jun磷酸化,进而导致p53蛋白诱导和细胞凋亡反应,随后导致Chel A的细胞转化抑制和化学预防活性。